Ongoing important trials
RAS(ON) inhibitor platform — GI solid tumor combinations
A Platform Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors
- Phase
- Phase I/II
- Recruitment
- Recruiting
- Results maturity
- No results
- Publication
- No publication
- Regulatory approval
- No regulatory approval
- NCT
- NCT06445062
- Registry checked
- 2026-10-29
- Editorial update
- 2026-10-29
Not a treatment recommendation. Experimental or ongoing research does not by itself replace standard care.
For patients
What is being studied? Safety of RAS-targeted drugs combined with chemotherapy is being studied in pancreatic and bowel cancers.
Why promising? Combines RAS(ON) agents with SoC to explore first-line and combination settings.
What is not proven? Comparative survival benefit; approved combination regimens.
Is this standard care today? This listing alone does not replace standard care; approval and guideline context require clinician judgment.
For clinicians
Multi-subprotocol platform; recruiting. Efficacy claims depend on subprotocol readouts.
Cancer / population: Pancreas, Colon, Multiple / solid tumors — RAS-mutant GI solid tümörler (CRC, PDAC alt protokolleri)
Intervention: RMC-6236 / RMC-9805 ± kemoterapi / hedefe yönelik ajanlar
Primary endpoint: Güvenlik, PK, RP2D; ön antitümör aktivite
Limitations: Heterojen alt protokoller; tek sonuç kartına indirgenemez.